Moderna Inc. Stock Advances 7.0%, Outperforms Peers
Dow Jones2026/09/24 20:33This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Moderna Inc. rose 7.0% to $194.82 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index remaining mostly unchanged at 26,939.37 and the Dow Jones Industrial Average falling 0.3% to 51,349.98.
Moderna Inc. hit a new 52-week high, surpassing its previous peak of $192.31, which the company reached on September 23rd.
The stock outperformed some of its peers, as Johnson & Johnson rose 0.6% to $270.68, Pfizer Inc. rose 0.8% to $28.41, and Gilead Sciences Inc. fell 1.11% to $149.69.
Trading volume totaled 16.4 million, compared to the 50-day average of 18.6 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 24, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US Dollar Index fell below the 101 mark, down 0.13% intraday.
Report: US-Iran conflict disrupts OPEC+ production increase schedule, capacity review postponed to mid-November
According to media reports, the capacity review work by OPEC+ has been delayed. Originally scheduled to be completed by the end of September 2026, it has now been postponed to mid-November. This theoretically still allows OPEC+ to discuss the related results at the plenary meeting in late November. The independent capacity assessment results will directly affect the production caps approved for each member country, and some member countries have already shown significant disagreements regarding quotas, putting pressure on the alliance’s stability.
Crypto prices
More
